Genotyping and Drug Susceptibility of Prototheca Strains in Dogs
Author Information
Author(s): Proskurnicka Angelika, Iskra Mateusz, Wronka Sylwia, Bakuła Zofia, Danesi Patrizia, de Farias Marconi Rodrigues, Ramos Portilho Fábio Vinícius, Garcia Ribeiro Márcio, Rösler Uwe, Kano Rui, Malik Richard, Jagielski Tomasz
Primary Institution: Department of Medical Microbiology, Institute of Microbiology, Faculty of Biology University of Warsaw
Hypothesis
To identify species and drug susceptibility profiles of an international collection of 28 Prototheca strains isolated from cases of protothecosis in dogs.
Conclusion
The study identifies P. bovis as the most frequent cause of protothecosis in dogs and suggests that efinaconazole could be a potential treatment.
Supporting Evidence
- 75% of the cases were caused by Prototheca bovis.
- Efinaconazole was the most potent drug tested with a median MIC of 0.125 mg/L.
- Fluconazole showed the lowest activity with a median MIC of 48 mg/L.
- The study provides a large microbiological analysis of protothecosis in dogs.
- Prototheca spp. are resistant to a wide spectrum of antimicrobial agents.
Takeaway
This study looked at a type of algae that can make dogs sick and found that one type is the most common cause of the illness. A new medicine might help treat it.
Methodology
Retrospective study using molecular typing and drug susceptibility testing on 28 Prototheca strains from dogs in 6 countries.
Limitations
The study is limited to a small number of strains and may not represent all cases of protothecosis in dogs.
Participant Demographics
Strains isolated from dogs in 6 countries: Germany, Brazil, Italy, Australia, Japan, and the United Kingdom.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website